- Home
- SUIG vs NMRA Comparison
SUIG vs NMRA Comparison
Compare SUIG & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUIG
- NMRA
- Stock Information
- Founded
- SUIG 2006
- NMRA 2019
- Country
- SUIG United States
- NMRA United States
- Employees
- SUIG N/A
- NMRA N/A
- Industry
- SUIG Finance Companies
- NMRA
- Sector
- SUIG Finance
- NMRA
- Exchange
- SUIG Nasdaq
- NMRA Nasdaq
- Market Cap
- SUIG 270.0M
- NMRA 291.5M
- IPO Year
- SUIG N/A
- NMRA 2023
- Fundamental
- Price
- SUIG $2.08
- NMRA $2.65
- Analyst Decision
- SUIG Strong Buy
- NMRA Buy
- Analyst Count
- SUIG 2
- NMRA 8
- Target Price
- SUIG $5.75
- NMRA $7.57
- AVG Volume (30 Days)
- SUIG 1.8M
- NMRA 3.5M
- Earning Date
- SUIG 11-12-2025
- NMRA 11-06-2025
- Dividend Yield
- SUIG N/A
- NMRA N/A
- EPS Growth
- SUIG N/A
- NMRA N/A
- EPS
- SUIG N/A
- NMRA N/A
- Revenue
- SUIG $3,608,807.00
- NMRA N/A
- Revenue This Year
- SUIG N/A
- NMRA N/A
- Revenue Next Year
- SUIG N/A
- NMRA N/A
- P/E Ratio
- SUIG N/A
- NMRA N/A
- Revenue Growth
- SUIG 11.58
- NMRA N/A
- 52 Week Low
- SUIG $1.13
- NMRA $0.61
- 52 Week High
- SUIG $8.66
- NMRA $11.57
- Technical
- Relative Strength Index (RSI)
- SUIG N/A
- NMRA 56.26
- Support Level
- SUIG N/A
- NMRA $2.55
- Resistance Level
- SUIG N/A
- NMRA $2.79
- Average True Range (ATR)
- SUIG 0.00
- NMRA 0.28
- MACD
- SUIG 0.00
- NMRA -0.04
- Stochastic Oscillator
- SUIG 0.00
- NMRA 33.89
About SUIG Sui Group Holdings Limited Common Stock
Sui Group Holdings Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.